Volume 17, Issue 6, June 2025

Review

Targeting the ubiquitin–proteasome system and drug therapy in colorectal cancer 
Ruixin Su, Yingying Shao, Qian Wang, Donghui Liu, Yitong Wang, Dexin Kong, Yuling Qiu
J Mol Cell Biol, Volume 17, Issue 6, June 2025, mjaf027, https://doi.org/10.1093/jmcb/mjaf027
Abstract | Full Text 

Articles

RNA-binding protein Rbm38 as a multifaceted post-transcriptional regulator in zebrafish pancreatic development
Xiangmin Zhang, Xianpeng Li, Rui Liu, Lu Wang, Yunchao Wang, Ailong Zhang, Shuaiqi Yang, Hongyan Li
J Mol Cell Biol, Volume 17, Issue 6, June 2025, mjaf025, https://doi.org/10.1093/jmcb/mjaf025
Abstract | Full Text 
Identification and characterization of a TGF-β-independent SMAD4–NFATc1–STAT3 regulatory axis 
Wukun Ouyang, Jiaying Hao, Qiankun Niu, Eugene F. Douglass Jr, Christian M. Beusch, David E. Gordon, Maggie Hall, Richard A. Moffitt, Yuhong Du, Xiulei Mo
J Mol Cell Biol, Volume 17, Issue 6, June 2025, mjaf028, https://doi.org/10.1093/jmcb/mjaf028
Abstract | Full Text 
Cover: The pathogenesis of colorectal cancer involves multiple signaling pathways. This figure summarizes the targeted protein
degradation strategies, primarily including proteolysis-targeting chimera (PROTAC), molecular glue, and small-molecule drugs,
that exert anti-colorectal cancer effects by harnessing the ubiquitin–proteasome system. See mjaf027 by Su et al. for details.